{"id":45107,"date":"2022-06-15T14:02:04","date_gmt":"2022-06-15T12:02:04","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/avilar-therapeutics-appoints-adam-muzikant-phd-as-chief-business-officer\/"},"modified":"2022-06-15T14:02:04","modified_gmt":"2022-06-15T12:02:04","slug":"avilar-therapeutics-appoints-adam-muzikant-phd-as-chief-business-officer","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/avilar-therapeutics-appoints-adam-muzikant-phd-as-chief-business-officer\/","title":{"rendered":"Avilar Therapeutics Appoints Adam Muzikant, PhD, as Chief Business Officer"},"content":{"rendered":"
\n

WALTHAM, Mass.–(BUSINESS WIRE)–Avilar Therapeutics<\/a>, a biopharmaceutical company focused on extracellular protein degradation, today announced the appointment of Adam Muzikant, PhD, as Chief Business Officer. Dr. Muzikant brings 18 years of business development experience creating and executing value-creating deals, from platform collaborations to commercial-stage product licenses and M&A, across a range of therapeutic areas and technologies at both private and public biopharmaceutical companies. In his role at Avilar, Dr. Muzikant will be responsible for corporate and business development as well as various business operations functions.\n<\/p>\n

<\/a>
<\/a><\/p>\n

\n\u201cWe are excited to welcome Adam to the Avilar leadership team during this time of significant growth of our company,\u201d said Daniel Grau, CEO and President of Avilar Therapeutics. \u201cHe brings exceptional expertise in business development and will play a central role in defining and executing our business, partnering, and financing strategy. Adam\u2019s strong track record of success in establishing diverse partnerships is an ideal fit for Avilar as we build a world-class company focused on extracellular protein degradation.\u201d\n<\/p>\n

\n\u201cI am thrilled to join the impressive team at Avilar and to help realize the full potential of the company\u2019s innovative ATAC (ASGPR Targeting Chimeras) protein degradation platform and the broad applications of this approach to create new impactful degrader medicines in many therapeutic areas,\u201d said Dr. Muzikant. \u201cI look forward to working in close collaboration with my new colleagues as we strive to make a meaningful difference in the lives of patients suffering from serious diseases.\u201d\n<\/p>\n

\nDr. Muzikant joins Avilar after serving as Chief Business Officer of Flexion Therapeutics (NASDAQ: FLXN), where he was instrumental in the sale of the company to Pacira BioSciences for up to $1B in enterprise value. While at Flexion, he was a member of the executive committee and drove construction of a pipeline of novel drug candidates through asset acquisitions, executed a China development and commercialization deal for ZILRETTA\u00ae, and orchestrated the R&D efforts of Flexion\u2019s Innovation Lab. Before joining Flexion, Dr. Muzikant was VP Business Development at Synta Pharmaceuticals, where he led the strategic transaction process culminating in a merger with Madrigal Pharmaceuticals. Prior to Synta, he held business development leadership positions at AMAG Pharmaceuticals, Inotek Pharmaceuticals, EPIX Pharmaceuticals, and Predix Pharmaceuticals, and also performed transaction\/strategic advisory work at Locust Walk for biotech and pharmaceutical companies. Dr. Muzikant holds a BS in Engineering from the University of California, San Diego and a PhD in Biomedical Engineering from Duke University.\n<\/p>\n

\nAbout Avilar Therapeutics<\/b>\n<\/p>\n

\nAvilar Therapeutics<\/a> is a biopharmaceutical company pioneering the discovery and development of extracellular protein degraders, a new frontier in targeted protein degradation. Avilar develops ATACs (ASGPR Targeting Chimeras<\/a>), a new class of protein degraders that shuttle disease-causing proteins from circulation to the endolysosome where the unwanted proteins are degraded. Avilar has built a proprietary ATAC platform that includes novel, high-affinity, small molecule ASGPR ligands and advanced modeling of the biophysics, pharmacokinetics, and pharmacodynamics of ATAC mediated endocytosis and degradation. The ATAC platform enables the modular design and synthesis of ATACs extendable across the extracellular proteome to a wide range of proteins involved in the pathogenesis of human diseases. Avilar is leveraging the ATAC platform to create a broad and diverse pipeline of first-in-class extracellular protein degraders. Avilar was founded and financed by RA Capital Management and based in Waltham, MA. For more information, please visit www.avilar-tx.com<\/a> and follow us on Twitter @Avilar_Tx<\/a> and on LinkedIn<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nKathryn Morris
\n
The Yates Network
\n
914-204-6412
\n
kathryn@theyatesnetwork.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

WALTHAM, Mass.–(BUSINESS WIRE)–Avilar Therapeutics, a biopharmaceutical company focused on extracellular protein degradation, today announced the appointment of Adam Muzikant, PhD, as Chief Business Officer. Dr. Muzikant brings 18 years of business development experience creating and executing value-creating deals, from platform collaborations to commercial-stage product licenses and M&A, across a range of therapeutic areas and technologies … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-45107","6":"format-standard","7":"category-industry"},"yoast_head":"\nAvilar Therapeutics Appoints Adam Muzikant, PhD, as Chief Business Officer - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/avilar-therapeutics-appoints-adam-muzikant-phd-as-chief-business-officer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Avilar Therapeutics Appoints Adam Muzikant, PhD, as Chief Business Officer - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"WALTHAM, Mass.–(BUSINESS WIRE)–Avilar Therapeutics, a biopharmaceutical company focused on extracellular protein degradation, today announced the appointment of Adam Muzikant, PhD, as Chief Business Officer. Dr. Muzikant brings 18 years of business development experience creating and executing value-creating deals, from platform collaborations to commercial-stage product licenses and M&A, across a range of therapeutic areas and technologies ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/avilar-therapeutics-appoints-adam-muzikant-phd-as-chief-business-officer\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-06-15T12:02:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220615005091\/en\/1486363\/21\/Avilar_CBO_Adam_Muzikant%2C_PhD.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/avilar-therapeutics-appoints-adam-muzikant-phd-as-chief-business-officer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/avilar-therapeutics-appoints-adam-muzikant-phd-as-chief-business-officer\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Avilar Therapeutics Appoints Adam Muzikant, PhD, as Chief Business Officer\",\"datePublished\":\"2022-06-15T12:02:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/avilar-therapeutics-appoints-adam-muzikant-phd-as-chief-business-officer\\\/\"},\"wordCount\":591,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/avilar-therapeutics-appoints-adam-muzikant-phd-as-chief-business-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220615005091\\\/en\\\/1486363\\\/21\\\/Avilar_CBO_Adam_Muzikant%2C_PhD.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/avilar-therapeutics-appoints-adam-muzikant-phd-as-chief-business-officer\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/avilar-therapeutics-appoints-adam-muzikant-phd-as-chief-business-officer\\\/\",\"name\":\"Avilar Therapeutics Appoints Adam Muzikant, PhD, as Chief Business Officer - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/avilar-therapeutics-appoints-adam-muzikant-phd-as-chief-business-officer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/avilar-therapeutics-appoints-adam-muzikant-phd-as-chief-business-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220615005091\\\/en\\\/1486363\\\/21\\\/Avilar_CBO_Adam_Muzikant%2C_PhD.jpg\",\"datePublished\":\"2022-06-15T12:02:04+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/avilar-therapeutics-appoints-adam-muzikant-phd-as-chief-business-officer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/avilar-therapeutics-appoints-adam-muzikant-phd-as-chief-business-officer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/avilar-therapeutics-appoints-adam-muzikant-phd-as-chief-business-officer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220615005091\\\/en\\\/1486363\\\/21\\\/Avilar_CBO_Adam_Muzikant%2C_PhD.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220615005091\\\/en\\\/1486363\\\/21\\\/Avilar_CBO_Adam_Muzikant%2C_PhD.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/avilar-therapeutics-appoints-adam-muzikant-phd-as-chief-business-officer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Avilar Therapeutics Appoints Adam Muzikant, PhD, as Chief Business Officer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Avilar Therapeutics Appoints Adam Muzikant, PhD, as Chief Business Officer - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/avilar-therapeutics-appoints-adam-muzikant-phd-as-chief-business-officer\/","og_locale":"en_US","og_type":"article","og_title":"Avilar Therapeutics Appoints Adam Muzikant, PhD, as Chief Business Officer - Pharma Trend","og_description":"WALTHAM, Mass.–(BUSINESS WIRE)–Avilar Therapeutics, a biopharmaceutical company focused on extracellular protein degradation, today announced the appointment of Adam Muzikant, PhD, as Chief Business Officer. Dr. Muzikant brings 18 years of business development experience creating and executing value-creating deals, from platform collaborations to commercial-stage product licenses and M&A, across a range of therapeutic areas and technologies ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/avilar-therapeutics-appoints-adam-muzikant-phd-as-chief-business-officer\/","og_site_name":"Pharma Trend","article_published_time":"2022-06-15T12:02:04+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220615005091\/en\/1486363\/21\/Avilar_CBO_Adam_Muzikant%2C_PhD.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/avilar-therapeutics-appoints-adam-muzikant-phd-as-chief-business-officer\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/avilar-therapeutics-appoints-adam-muzikant-phd-as-chief-business-officer\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Avilar Therapeutics Appoints Adam Muzikant, PhD, as Chief Business Officer","datePublished":"2022-06-15T12:02:04+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/avilar-therapeutics-appoints-adam-muzikant-phd-as-chief-business-officer\/"},"wordCount":591,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/avilar-therapeutics-appoints-adam-muzikant-phd-as-chief-business-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220615005091\/en\/1486363\/21\/Avilar_CBO_Adam_Muzikant%2C_PhD.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/avilar-therapeutics-appoints-adam-muzikant-phd-as-chief-business-officer\/","url":"https:\/\/pharma-trend.com\/en\/avilar-therapeutics-appoints-adam-muzikant-phd-as-chief-business-officer\/","name":"Avilar Therapeutics Appoints Adam Muzikant, PhD, as Chief Business Officer - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/avilar-therapeutics-appoints-adam-muzikant-phd-as-chief-business-officer\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/avilar-therapeutics-appoints-adam-muzikant-phd-as-chief-business-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220615005091\/en\/1486363\/21\/Avilar_CBO_Adam_Muzikant%2C_PhD.jpg","datePublished":"2022-06-15T12:02:04+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/avilar-therapeutics-appoints-adam-muzikant-phd-as-chief-business-officer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/avilar-therapeutics-appoints-adam-muzikant-phd-as-chief-business-officer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/avilar-therapeutics-appoints-adam-muzikant-phd-as-chief-business-officer\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220615005091\/en\/1486363\/21\/Avilar_CBO_Adam_Muzikant%2C_PhD.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220615005091\/en\/1486363\/21\/Avilar_CBO_Adam_Muzikant%2C_PhD.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/avilar-therapeutics-appoints-adam-muzikant-phd-as-chief-business-officer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Avilar Therapeutics Appoints Adam Muzikant, PhD, as Chief Business Officer"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/45107","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=45107"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/45107\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=45107"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=45107"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=45107"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}